Autonomix Medical to Present at LSI USA ’26
Rhea-AI Summary
Autonomix Medical (NASDAQ: AMIX) announced that Brad Hauser, President and CEO, will present at LSI USA ’26 on March 17, 2026 at 9:15 AM PT. Management will be available for in-person one-on-one meetings with registered, qualified investors attending the conference.
The presentation is accessible to registered attendees only. LSI USA '26 is a global medtech summit for executives, investors and innovators featuring keynote sessions, panels and startup presentations.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AMIX fell 7.56% while momentum-screened peers showed mixed moves, with 1 up and 3 down. HSDT, PAVM, TIVC, and MOVE featured in momentum data, and sector text notes median peer change near -2.7%, suggesting broader medical-device pressures alongside AMIX’s decline.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Innovation competition | Positive | +2.2% | Selection for CRT 2026 Best Innovation oral presentation highlighting core technology. |
| Mar 04 | Clinical podium data | Positive | +3.1% | Top Abstract podium selection for novel transvascular RF peripheral nerve neurolysis data. |
| Feb 25 | Management communication | Positive | +8.0% | CEO Corner segment detailing publication strategy and scientific validation efforts. |
| Feb 19 | Clinical data presentation | Positive | +1.2% | Announcement of new long-term pain mitigation data in pancreatic cancer at SSO 2026. |
| Jan 28 | Clinical data ePoster | Positive | -0.1% | Final RF ablation pain mitigation data to be presented at SIO 2026 ePoster session. |
Recent scientific and conference-related announcements have typically produced modest positive single-day moves, with only one slight negative reaction.
Over the last several months, Autonomix has repeatedly highlighted its technology through conference presentations and clinical data. Events on Jan 28, 2026, Feb 19, 2026, Mar 4, 2026, and Mar 5, 2026 all focused on podium talks and innovation competitions, generally leading to small positive price reactions. A Feb 25, 2026 management communication about publication strategy also aligned with a stronger upside move. Today’s LSI USA ’26 presentation fits this pattern of visibility-focused news rather than fundamental financial change.
Regulatory & Risk Context
An effective S-3 shelf from Nov 26, 2025 registers 13,504,998 warrant-related resale shares. While Autonomix does not receive resale proceeds, it could obtain up to $7.7 million if Common Warrants are exercised in cash, with prior usage reflected in a Dec 12, 2025 424B3. This structure adds potential dilution over time.
Market Pulse Summary
This announcement adds another visibility event, with Autonomix presenting at LSI USA ’26 on Mar 17, 2026 and holding one-on-one investor meetings. It follows a series of conference and data-related communications in early 2026 that modestly supported the stock. Regulatory filings highlight a nine‑month net loss of $14.0 million, cash of $9.9 million, going‑concern disclosures, a Nasdaq bid-price deficiency notice, and warrant and equity facilities, including potential proceeds of up to $7.7 million, underscoring capital and dilution risks investors may monitor alongside future data updates.
AI-generated analysis. Not financial advice.
THE WOODLANDS, TX, March 11, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Brad Hauser, President and Chief Executive Officer of Autonomix will present at LSI USA ’26 on Tuesday, March 17, 2026 at 9:15 AM PT.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference.
The in-person presentation will be accessible to those registered to attend the event. For more information, please visit the conference website.
LSI USA '26, organized by Life Science Intelligence, is a leading global medtech summit that convenes executives, investors and innovators from across the healthcare industry. The event features keynote sessions, expert panels and startup presentations focused on advancing medical technology, fostering partnerships and accelerating innovation across the life sciences sector.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.” Forward-looking statements in this press release include expectations regarding the potential effectiveness and clinical benefits of Autonomix's nerve-targeted treatments for pancreatic cancer pain and other conditions.
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 29, 2025, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of this press release and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
When will Autonomix (AMIX) present at LSI USA ’26?
Will Autonomix management meet with investors at LSI USA ’26?
How can investors attend Autonomix's (AMIX) presentation at LSI USA ’26?
Who from Autonomix will present at LSI USA ’26 and what is their role?
What topics will Autonomix cover at LSI USA ’26 and is the session public?
